Raymond James Financial’s abrdn Life Sciences Investors HQL Stock Holding History

Raymond James Financial’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8M	Buy	689,134 +27,822	+4%	+$492K	﹤0.01%	1868
2026 Q1	$10.8M	Buy	661,312 +64,257	+11%	+$1.07M	﹤0.01%	1958
2025 Q4	$10M	Buy	597,055 +174,024	+41%	+$2.92M	﹤0.01%	1962
2025 Q3	$6.56M	Buy	423,031 +47,071	+13%	+$644K	﹤0.01%	2254
2025 Q2	$4.82M	Buy	375,960 +63,429	+20%	+$782K	﹤0.01%	2403
2025 Q1	$3.97M	Buy	312,531 +74,061	+31%	+$1M	﹤0.01%	2479
2024 Q4	$3.13M	Buy	+238,470	New	+$3.44M	﹤0.01%	2638

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Raymond James Financial's HQL Position: Q2 2026 in Review

Raymond James Financial increased its abrdn Life Sciences Investors (HQL) stake by 4.2% in Q2 2026, buying an estimated $492K and bringing the position to 689,134 shares worth $13.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1868.

Raymond James Financial first reported a position in HQL in Q4 2024 and has held it in 7 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Raymond James Financial held 689,134 shares of abrdn Life Sciences Investors worth $13.8M as of Q2 2026.
Raymond James Financial bought 27,822 abrdn Life Sciences Investors shares in Q2 2026, an estimated $492K.
abrdn Life Sciences Investors made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1868 holding.
Raymond James Financial first reported a position in abrdn Life Sciences Investors in Q4 2024 and has held it in 7 quarters since.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.